At its Meeting on 6 June 2022, the Transparency Council adopted Position No. 54/2022 on the evaluation of Dupixent (dupilumabum) under the drug programme:,,Treatment of patients with severe atopic dermatitis (ICD-10: L20)”.
At its Meeting on 6 June 2022, the Transparency Council adopted Position No. 54/2022 on the evaluation of Dupixent (dupilumabum) under the drug programme:,,Treatment of patients with severe atopic dermatitis (ICD-10: L20)”.